Jump to content
  • Sign Up
0
Scott Adams

FDA grants fast track designation to Alvine celiac disease therapeutic - Pharmaceutical Business Review

Rate this topic

Recommended Posts

FDA grants fast track designation to Alvine celiac disease therapeutic

Pharmaceutical Business Review

"Building on the data from our earlier phase 2A trial that demonstrated the ability of ALV003 to diminish gluten-induced intestinal injury in well-controlled celiac disease patients, we look forward to pursuing phase 2 and phase 3 trials under the Fast ...

View the full article

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
0

×